

Clinical Insights Program

A personalized approach to optimizing patient outcomes¹⁻³

The Clinical Insights Program provides Therapeutic Drug Monitoring (TDM) at **no cost for eligible patients***

Please see the full Prescribing Information, including **Boxed WARNING**, and Medication Guide for IDACIO[®] (adalimumab-aacf) at www.idaciohcp.com.



* Phlebotomy-related costs may be incurred at non-participating locations.




Why Therapeutic Drug Monitoring?

A validated approach to personalized disease management^{1,3}

Therapeutic drug monitoring (TDM) measures serum drug and antibody levels and can arm you with important data to help optimize your patient's treatment journey.

The goal of TDM is to help healthcare professionals:¹⁻³

- Measure drug concentrations to inform physicians of drug exposure or identify the presence of anti-drug antibodies
- Determine if patient symptoms may be caused by insufficient drug levels or anti-drug antibodies due to treatment
- Achieve more durable drug responses that may result in reduced flares and allow for patients to stay in remission longer



The test report will provide valuable patient data, including serum levels of adalimumab (ADA) and antibodies-to-adlimumab (ATA).



Anser[®] ADA for IDACIO[®] is a TDM test developed and validated by Prometheus Laboratories to measure serum levels of adalimumab and antibodies-to-adalimumab from one blood sample.

Fresenius Kabi's Clinical Insights Program will cover the cost of up to two Anser[®] ADA for IDACIO[®] tests per year.*



Patients will need to meet the following eligibility criteria*:

- Prescribed or already using IDACIO®
- 18 years of age or older
- Diagnosed with RA or IBD
- Commercially insured or uninsured


Your patients may benefit from the KabiCare Patient Support Program's other offerings, however they do not have to be enrolled in KabiCare to receive the test. To find out more, visit kabicare.us.





Quality Support for your patients and their clinical management

A simplified process providing validated results



Write prescription

Prescribe IDACIO[®] (adalimumab-aacf) and confirm your patient's eligibility for the Anser[®] ADA[®] for IDACIO[®] test.

Order test kit

Fill out the Anser® ADA® for IDACIO® Test Kit order form at kabicare.us/hcp/clinicalinsights or call 1-877-216-3677 to order test kits.

The test kit may be delivered to your office, your patient's home, or the phlebotomy lab.

Complete the test requisition form

Complete the test requisition form contained in the test kit. It's also available for download at kabicare.us/hcp/clinicalinsights.

Only the Anser® ADA for IDACIO® test requisition form will be accepted.

Coordinate sample collection*

Instruct the patient to bring the test kit and completed requisition form to their blood draw appointment if the practice will not be collecting the sample.

Once the sample has been collected, follow the shipping instructions on the back of the test requisition form.



Interpret report

The Anser® ADA for IDACIO® report provides valuable data about how the patient is responding to treatment and help support the decision-making process.

Test results are faxed or mailed to your office approximately 3-5 business days from the date the blood sample was received at Prometheus® Laboratories for testing.

Consult with your patient

As with other chronic diseases, you and your patient will make many decisions about their care that can have a significant impact on their quality of life.

Adding TDM as part of your overall clinical care can help optimize therapy with the goal of improving outcomes and reducing overall cost.²⁻⁴

Prometheus Laboratories

The Clinical Insights Program from Fresenius Kabi is offered in collaboration with Prometheus® Laboratories.

Prometheus[®] Laboratories is a specialty laboratory enabling precision-guided care by offering clinical testing services that help clinicians improve outcomes across the patient journey through optimization and monitoring of therapeutic care.

Prometheus[®] Laboratories offers you 24/7 online access to laboratory test results through their online platform, ProNet.

For general questions or information about mobile phlebotomy options and participating locations, please call Client Services at (877)-216-3677, or go to prometheuslab.com

Clinical Insights Program

Helps optimize therapy and supports improved outcomes for your patients.¹⁻³

- Anser[®] ADA for IDACIO[®] is a validated therapeutic drug monitoring test (TDM) that measures serum drug and antibody levels to assess safety and efficacy of this therapeutic medication in support of durable drug response.⁵
- The Clinical Insights Program provides Anser® ADA for IDACIO® at no cost for eligible patients for up to two tests per year for eligible patients.*

<section-header>

Anser[®]ADA[®]

To order your test kit:

Call toll-free in the U.S.: 1-877-216-3677 Monday through Friday 6:00am - 4:30pm Pacific Time

OR

Access the order form at: kabicare.us/hcp/ clinicalinsights

At Fresenius Kabi we go beyond supplying medicines.

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion, clinical nutrition, and specialty pharmaceuticals. Our products and programs are designed to help care for critically and chronically ill patients. For more than a century, we've delivered innovative therapies that are safe, efficient, and affordable. Recognized for our proven track record of quality, reliability, and consistency, we produce our medications in 90 state-of-the-art plants around the world. From essential injectable medicines to advanced systems used to maintain and protect the nation's blood supply. We're committed to making sure that patients have accurate and transparent information as new medication options come to market.

* Phlebotomy-related costs may be incurred at non-participating locations.

References: 1. Krieckaert CL, van Tubergen A, Gehin JE, et al. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases 2023 May ; 82:65-73. 2. Irving PM, Gecse KB. Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives. *Gastroenterology*. 2022 Apr;162(5):1512-1524. doi: 10.1053/j.gastro.2022.02.014. Epub 2022 Feb 12. PMID: 35167865. 3. Vermeire S, Dreesen E, Papamichael K, Dubinsky MC. How, When, and for Whom Should We Perform Therapeutic Drug Monitoring? *Clin Gastroenterol Hepatol*. 2020 May;18(6):1291-1299. doi: 10.1016/j.cgh.2019.09.041. Epub 2019 Oct 4. PMID: 31589978. 4. Martelli L, Olivera P, Roblin X, Attar A, Peyrin-Biroulet L. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. *J Gastroenterol*. 2017 Jan;52(1):19-25. doi: 10.1007/s00535-016-1266-1. Epub 2016 Sep 24. PMID: 27665099. 5. Therapeutic drug monitoring. MedlinePlus. Accessed May 15, 2023. https://medlineplus.gov/labtests/therapeutic-drug-monitoring/.

Anser® ADA for IDACIO® is a laboratory-developed tests that was developed and validated under Federal CLIA laboratory guidelines by Prometheus Laboratories. Prometheus and Anser®, are registered trademarks of Prometheus Laboratories Inc, San Diego, California.

